Protocol to synthesize sequence-controlled glycooligomers for tumor targeting in mice

Qina Lin; Jie Chen; Yichuan Zhang; Quan Gao; Liwei Zhu; Qi Xing; Jin Geng

doi:10.1016/j.xpro.2024.103029

Protocol to synthesize sequence-controlled glycooligomers for tumor targeting in mice

STAR Protoc. 2024 May 8;5(2):103029. doi: 10.1016/j.xpro.2024.103029. Online ahead of print.

Authors

Qina Lin¹, Jie Chen², Yichuan Zhang², Quan Gao³, Liwei Zhu³, Qi Xing⁴, Jin Geng⁵

Affiliations

¹ Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518059, China; University of Chinese Academy of Sciences, Beijing 101408, China.
² Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518059, China; School of Pharmacy, Henan University, Kaifeng 475004, China.
³ Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518059, China.
⁴ Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518059, China. Electronic address: q.xing@siat.ac.cn.
⁵ Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518059, China; Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, Shenzhen 518000, China. Electronic address: jin.geng@siat.ac.cn.

Abstract

Due to the higher and more rapid consumption of carbohydrates by cancer cells compared to normal cells, carbohydrates can be effectively employed as a targeted therapeutic strategy for tumor treatment. Here, we present a protocol for synthesizing sequence-controlled glycooligomers using both solution-phase and solid-phase systems. We outline detailed procedures for evaluating the safety and tumor-targeting properties of the sequence-controlled glycooligomers in vivo. For complete details on the use and execution of this protocol, please refer to Chen et al.¹.

Keywords: Cancer; Chemistry; Model Organisms.